AXSM Axsome Therapeutics Inc
Price (delayed)
$91.75
Market cap
$4.4B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$6.56
Enterprise value
$4.28B
Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people
Highlights
The revenue has soared by 60% YoY and by 16% from the previous quarter
AXSM's gross profit has surged by 58% year-on-year and by 16% since the previous quarter
The net income has plunged by 67% YoY and by 4.1% from the previous quarter
The equity has dropped by 63% year-on-year and by 29% since the previous quarter
Key stats
What are the main financial stats of AXSM
Market
Valuations
Earnings
Shares outstanding
48M
Market cap
$4.4B
Enterprise value
$4.28B
Price to earnings (P/E)
N/A
Price to book (P/B)
42.37
Price to sales (P/S)
14.97
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.68
Revenue
$291.49M
EBIT
-$305.72M
EBITDA
-$297.03M
Free cash flow
-$168.02M
Per share
Balance sheet
Liquidity
EPS
-$6.56
Free cash flow per share
-$3.53
Book value per share
$2.17
Revenue per share
$6.13
TBVPS
$10.22
Total assets
$548.23M
Total liabilities
$445.37M
Debt
$190.6M
Equity
$102.85M
Working capital
$276.46M
Debt to equity
1.85
Current ratio
2.48
Quick ratio
2.34
Net debt/EBITDA
0.42
Margins
Efficiency
Dividend
EBITDA margin
-101.9%
Gross margin
90.3%
Net margin
-105.9%
Operating margin
-104.9%
Return on assets
-54.1%
Return on equity
-174.5%
Return on invested capital
-164.7%
Return on capital employed
-84.5%
Return on sales
-104.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AXSM stock price
How has the Axsome Therapeutics stock price performed over time
Intraday
0.79%
1 week
-2.07%
1 month
8.04%
1 year
11.6%
YTD
15.28%
QTD
13.98%
Financial performance
How have Axsome Therapeutics's revenue and profit performed over time
Revenue
$291.49M
Gross profit
$263.23M
Operating income
-$305.72M
Net income
-$308.55M
Gross margin
90.3%
Net margin
-105.9%
The company's operating income has shrunk by 76% YoY and by 4.4% QoQ
The net income has plunged by 67% YoY and by 4.1% from the previous quarter
The revenue has soared by 60% YoY and by 16% from the previous quarter
AXSM's gross profit has surged by 58% year-on-year and by 16% since the previous quarter
Growth
What is Axsome Therapeutics's growth rate over time
Valuation
What is Axsome Therapeutics stock price valuation
P/E
N/A
P/B
42.37
P/S
14.97
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.68
The EPS has plunged by 53% YoY and by 2% from the previous quarter
The P/B is 77% higher than the last 4 quarters average of 23.8 and 11% higher than the 5-year quarterly average of 37.9
The equity has dropped by 63% year-on-year and by 29% since the previous quarter
The revenue has soared by 60% YoY and by 16% from the previous quarter
The price to sales (P/S) is 5% higher than the last 4 quarters average of 14.1
Efficiency
How efficient is Axsome Therapeutics business performance
The ROE has plunged by 56% YoY and by 30% from the previous quarter
AXSM's ROA is down by 23% YoY and by 7% QoQ
The ROS has contracted by 10% YoY but it has grown by 10% from the previous quarter
The company's return on invested capital fell by 4.6% QoQ
Dividends
What is AXSM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AXSM.
Financial health
How did Axsome Therapeutics financials performed over time
Axsome Therapeutics's total assets is 23% more than its total liabilities
The quick ratio has contracted by 47% YoY and by 22% from the previous quarter
AXSM's current ratio is down by 45% year-on-year and by 23% since the previous quarter
Axsome Therapeutics's debt is 85% higher than its equity
The debt to equity has soared by 180% YoY and by 41% QoQ
The equity has dropped by 63% year-on-year and by 29% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.